Simple Summary Unlike B cell malignancies, the progress on generating an adoptive T cell
therapy for relapsed/refractory acute myeloid leukemia (AML) remains insufficient. This …

Hematologic malignancies (HMs) pose a serious threat to patients' health and life, and the
five-year overall survival of HMs remains low. The lack of understanding of the pathogenesis …

Acute myeloid leukemia (AML) remains an elusive disease to treat, let alone cure, even after
highly intensive therapies such as stem cell transplants. Adoptive cell therapeutic strategies …

Tumors can be classified into distinct immunophenotypes based on the presence and
arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot …

Simple Summary Despite intensive standard treatment, acute myeloid leukemia (AML)
continues to be associated with a poor prognosis due to treatment resistance and a high risk …

Neoantigens derived from non-synonymous somatic mutations are restricted to malignant
cells and are thus considered ideal targets for T cell receptor (TCR)-based immunotherapy …

Acute myeloid leukemia (AML) is a deadly disease and the most common leukemia in adult
with clonal heterogeneity and abnormity in myeloid lineages, which has been recognized …

Recurrent and/or refractory (R/R) pediatric acute myeloid leukemia (AML) remains a
recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune …

Despite the results achieved with the evolution of conventional chemotherapy and the
inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is …

Chimeric antigen receptor (CAR) T therapies are being developed for acute myeloid
leukemia (AML) on the basis of the results obtained for other haematological malignancies …